All In Biotech

Investigational drug · Phase 3

ATB-1011

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Essential Hypertension, Diabetes Mellitus, Type 2.

Phase 3

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

4

Any phase or sponsor naming "ATB-1011"

First trial start

2022

Nov 16, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ATB-1011", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Essential Hypertension
  • Diabetes Mellitus, Type 2

Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "ATB-1011" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Essential Hypertension

  • DWC202314Phase 32 trials

    Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension

  • DWC202314PPhase 32 trials

    Daewoong Pharmaceutical Co. LTD. · Essential Hypertension, Hypertension

  • Shenzhen Salubris Pharmaceuticals Co., Ltd. · Essential Hypertension

  • AD-227APhase 31 trial

    Addpharma Inc. · Essential Hypertension

  • AD-227BPhase 31 trial

    Addpharma Inc. · Essential Hypertension

  • AD-227CPhase 31 trial

    Addpharma Inc. · Essential Hypertension

  • ATB-1012Phase 31 trial

    Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2

  • ATB-1013Phase 31 trial

    Autotelicbio · Essential Hypertension, Diabetes Mellitus, Type 2

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.